← boardnext 2026-12next 2027-06
TARA
Protara Therapeuticsdistress 3/10 · well-funded / low risk$4.00-2%today-47% from 52w high
Lead: Non-Muscle Invasive Bladder Cancer (NMIBC)
Revenue
pre-revenue
Liquidity
$177M
Runway
2.8 yrs
Shares 1y
+46%
Price & events
-32.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-1.8%
1W
+0.1%
1M
-23.9%
3M
-35.3%
6M
+18.1%
1Y
+67.6%
2Y
-52.2%
5Y
-83.2%
All
Overview
- Market Cap
- $225.10M
- Volume
- 37.41K
- 52 Week Range
- $3.03 – $7.56
- Total Shares
- 56.20M
- Float Shares
- 49.16M
- Short %
- 7.85%
- % Held by Insiders
- 2.42%
- % Held by Institutions
- 81.10%
- RVOL
- 0.05x
- Beta
- 1.48
Pipeline stages · 2 programs
TARA-002
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Choline Chloride for Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | TARA-002rare pediatricorphan | Lymphatic Malformation | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 2/3 | Choline Chloride for Injectionorphanfast track | Choline Deficiency, Liver Injury | — | recruiting |
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 3 | TARA-002, Investigator's Choice of Intravesical Chemotherapyrare pediatricorphan | Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | — | recruiting |
| 2031-10 Estimated 50% readout ~2031-11-15 | Phase 2 | TARA-002rare pediatricorphan | Non-muscle Invasive Bladder Cancer | — | recruiting |
Catalyst news & presentations · 7
- second half of 2026Guided 55%trial initiationsecondaryPhase 3TARA-002 · Planned initiation of ADVANCED-3 registrational trial in BCG-Naïve patientsSEC 8-K
- second half of 2026Guided 55%enrollment completesecondaryPhase 2TARA-002 · Expected completion of enrollment in BCG-Unresponsive registrational cohort of ADVANCED-2 trialSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- February 27, 2026conferencedata presentationsecondaryPhase 2TARA-002 · Poster session at ASCO GU Cancer Symposium presenting updated interim data from Phase 2 ADVANCED-2 trialSEC 8-K
- by the end of 2025readoutPhase 2TARA-002 · Updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patientsSEC 8-K
- mid-2025readoutPhase 2TARA-002 · Initial data from 12-month evaluable patientsSEC 8-K
- December 5, 2024conferencedata presentationsecondaryPhase 2TARA-002 · Interim results presented at 2024 SUO ConferenceSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $27 (+563% upside) · 7 analysts
- 2026-05-20OppenheimerOutperform
- 2026-05-14JP MorganOverweight
- 2026-04-29HC Wainwright & Co.Buy
- 2026-03-04JP MorganOverweight
- 2026-02-10HC Wainwright & Co.Buy
- 2026-01-07Piper SandlerOverweight
Competitors — Non-Muscle Invasive Bladder Cancer (NMIBC)
- none identified
Recent news
- 2026-07-22 - GlobeNewswire
- 2026-07-21What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
- 2026-07-21Forest-bathing trail opens at Tara Lila, first of its kind in Wisconsin - Vilas County News-Review
- 2026-07-21Royal Caribbean (RCL) Appoints Former Airbnb Executive Tara Bunch To Its Board - Yahoo Finance
- 2026-07-21Watch: Toxic's New Song Madhosh Offers Fans A Glimpse Of Yash And Tara Sutaria's Sizzling Chemistry - NDTV
- 2026-07-21The Journey, Not the Stops: Real Life Lessons From Mary Kay's Executive Tara Eustace on Building Confidence - Morningstar
- 2026-07-21HANA Voices Concern Over Sentencing of 21-Year-Old Student Tara Farhangian to Prison Flogging and Exile - Hana Human Rights Organization
- 2026-07-21Tara Kumar’s Top New Tunes: July 2026 - clashmusic.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.